Team 07 : Stress Adaptation and Tumor Escape

Team leader: Dr Philippe P. Juin (lab director)

Research Projects

Our Team is based at IRS-UN in Nantes and ICO in Saint-Herblain. Our goal is to identify vulnerabilities and markers of aggressive cancers by exploring how individual, yet concerted, cell phenotypes contribute to progression and therapeutic resistance. We view tumor escape as resulting from the aberrant survival of malignant or non-malignant cells that adapt to diverse tumor related stresses. We consider that such adaptation has to be mapped to classify patients, and targeted to improve treatments. We focus our studies, albeit non exclusively, on breast cancers. Recent cell-by-cell descriptions showed high intratumoral heterogeneity of epithelial cells (of distinct types/states), at least partly favored by epithelial plasticity programs (such as Epithelial to Mesenchymal Plasticity- EMP) and co-evolving with a pro-tumoral cellular microenvironment. To explore how these pseudo-organs are built on “undead cells”, we address distinct themes, animated by specific research groups (encompassing scientists, students and technical staff supervised by a PI). The tight connections between groups are not only ensured by the complementarity between subjects but also by the partial mutualization of technical staff expert in molecular biology, ex vivo cultures derived from human samples or in vivo models, and by the sharing of bio-analytical approaches (led by dedicated scientists). One of the strengths of our team is that it brings together scientists with very diverse backgrounds going from cell biology to molecular biology with a clear attraction for innovation and new technologies. Our positioning at the interface of upstream research and transfer research allows us, by taking full advantage of the complementary expertise of the researchers, clinicians and veterinarians who constitute our team, to study samples derived from patients in addition to relevant models of cancer pathology.

How do malignant cells survive despite tumor related stresses, in response to cytotoxic chemotherapy and/or immune checkpoint inhibition? Our studies of intrinsic regulation of cell survival are based on the notion that various stimuli during tumor progression (akin to these during morphogenesis) and most anti-cancer therapies alter mitochondrial integrity, which is tightly controlled by BCL-2 family proteins (Juin et al. 2013). The group BH3 supervised by Laurent Maillet explores how these proteins engage into protein complexes to favor survival, how these complexes are regulated by novel partners (Vuillier, 2018) and how they are perturbed pharmacologically by BH3 mimetics (Pécot, 2016). A critical feature is the C-terminal mediated anchoring of these proteins at subcellular membranes such as the mitochondrial outer membrane, and we recently hinted that BCL-2 proteins might regulate mitochondrial scaffolding (Belaid, BioRxiv). The group Mitochondria supervised by Lisenn Lalier investigates how dynamic exchanges between these organelles and other subcellar compartments in response to stress contribute to adaptive survival (Lalier 2022, Mignard 2020).

Which intercellular communications contribute to aberrant cell survival? Recent atlases of breast cancers show that distinct epithelial states are close to specific non-malignant cell types. Cell compositions appear to follow ecotype rules that need to be understood with the characterization of how cells dialog with each other, and of extrinsic signals related to cell survival. The group Cancer Associated Fibroblasts and Apoptosis Resistance (CARE) supervised by Frédérique Souazé studies the influence of this major component of breast cancers on malignant cell survival (Louault, 2019), in treatment naïve and chemotherapy treated cancers, and seeks for vulnerabilities specifically associated with the pathological differentiation of these cells in the tumor microenvironment (Bonneaud, 2022). We recently established that the cytosolic DNA sensing pathway is activated in malignant cells by antimitotic agents (Lohard, 2020). The group Therapy Induced Cell Death (TICD) supervised by Sophie Barillé-Nion investigates the dialog between malignant and immune cells in the context of therapy. Emphasizing our interconnected nature, this group is naturally led to study the different modes of cell death triggered by treatments, in coordination with the groups described above.

How does plasticity contribute to pathogenic cell survival? Independently of any notion of oligoclonality, EMP (and possibly other programs) maintains intra-tumor heterogeneity through the dynamic induction of phenotypic conversions, and creates aggressive subpopulations within tumor ecotypes. The group Cell Plasticity and Primary Cilia and disease (CP2C) supervised by Vincent Guen investigates how hybrid E/M programs are associated with primary ciliogenesis, and how the latter contributes to survival, self-renewal, tissue regeneration and tumor relapse (Wilson, 2021). The pro-tumoral effects of EMP are further enhanced by the fact that it promotes a hybrid E/M state leading cell invasion and that the expression of vimentin, characteristic of this state, is necessary for invasion (Grasset 2022). The group Metastasis recently created by Eloïse Grasset further explores programs, such as EMP and Vimentin in particular that allow malignant cells to adapt to stress encountered during metastatic colonization, including the sequential steps of metastatic seeding and of outgrowth.

These studies are complemented by two transversal axis. The group Epigenetic, epitranscriptomic and transcriptomic reprogramming (Epi2TR) supervised by Pierre-François Cartron studies how base modifications in promoter regions and miRNAs regulate gene expression and cell survival, shape epithelial heterogeneity and influence intercellular communications. The pioneering identification of miRNA modifications (Cheray 2020) is of particular interest as modified miRNAs can be found in exosomes (contributing to horizontal information transfer) and in blood samples (as « epimarks » of treatment-induced counter-selections providing a window for measuring longitudinal evolutions, Briand, 2020). Our phenotypic characterizations rely on bulk and single cell RNA sequencing and the corresponding analytical needs (and related questions) are assumed by the development of state of the art bioinformatic approaches by Fabien Gautier together with Agnès Basseville and Jennifer Derrien, contributing to subjects apprehended by all groups. Along another transversal axis, we develop novel methodologies together with François Guillonneau head of the oncoproteomics group (managing the PROT'ICO platform), for in-depth proteome characterizations. The available tools readily allow intracellular exploration of protein complexes, subcellular proteomes, soluble and exosomal proteins, and tissue composition. Compared to mainstream bulk proteome analysis, recently acquired tools at the ICO proteomics facility such as the LASER microdissection LMD-7 microscope will allow to choose cells or specific structures or compartments from biopsies to undergo spatially-resolved proteome analysis in order to provide a fine grain description of breast cancers microenvironment as cellular ecosystems shaped by stress responses. Moreover the CellenOne-Neo nanopipetting device makes microbulk proteome analysis from a few cells at grasp range with higher throughput and robustness of analysis.

Cancer Associated Fibroblasts (CAFs) "Organemone"
by immunocytochemistry

Equipe 7 photo

Latest news

Congrats Vincent Guen for the Prix Ruban Rose Avenir 2025 ! Link to the video

Laurent Maillet and co-authors are pleased to share their latest publication - well done! Click here to read more

A big thank you to the Ligue contre le Cancer for its long term support of the SATE team to support its research on the identification of MCL-1 dependent compensatory mechanisms contributing to cellular heterogeneity in aggressive breast cancers

Philippe Juin, Winner of the Avenir 2022 Research Grant awarded by Association Ruban Rose for a project of collaboration between Team 7 and Team 12 on breast cancer Click here to watch the interview! you tube

Congratulations to Vincent Guen, identified as a promising young researcher by the program "Etoiles Montantes" of the Region Pays de la Loire

Recent key publications

Please click on this link to see our recent key publications

Medical associated staff

Mario Campone, PU-PH ICO
Mathilde Dupé, PH ICO
Jean-Sébastien Frenel, PU-PH ICO
Pascal Jézéquel, PH ICO
Olivier Kerdraon, PH ICO
Judith Raimbourg, PH ICO
Frédérique Nguyen, Associated professor ONIRIS
Marie Robert, PH ICO

Key publications of the team since 2020

Maillet L, Fétiveau A, Lalier L, Martin N, Barillé-Nion S, Guette C, Gautier F, Téletchéa S, Juin PP. Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism. Nature Commun. 2025 doi.org/10.1038/s41467-025-65509-1
Cordier C, Jézéquel P, Campone M, Panloup F, Basseville A. HABiC: an algorithm based on the exact computation of the Kantorovich-Rubinstein optimizer for binary classification in transcriptomics. Bioinformatics, 2025. DOI: 10.1093/bioinformatics/btaf310
Besson JM, Etcheverry A, Nadaradjane A, Bougras-Cartron G, Aubry M, Frenel JS, Chevanieu A, Lopez M, Mosser J, Cartron PF. Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMT^methylated/DGKI^methylated glioblastoma. Clin Epigenetics. 2025 Aug 30;17(1):146. doi: 10.1186/s13148-025-01943-8. PMID: 40886022; PMCID: PMC12398979.
Lefebvre CC, Giowachini P, Derrien J, Naour M, Corre I, Thirouard L, Douillard E, Chiron D, Guillonneau F, Treps L, Campone M, Juin PP, Souazé F. MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblasts. Cell Death Dis. 2025 Aug 9;16(1):603. doi: 10.1038/s41419-025-07920-6. PMID: 40783386; PMCID: PMC12335522.
Jézéquel P, Lasla H, Gouraud W, Basseville A, Michel B, Frenel JS, Juin PP, Ben Azzouz F, Campone M. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype Breast Cancer. 2024 Sep;31(5):825-840. doi: 10.1007/s12282-024-01597-z.
Nocquet L, Roul J, Lefebvre CC, Duarte L, Campone M, Juin PP, Souazé F. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts. Sci Rep. 2024 Jun 19;14(1):14177. doi: 10.1038/s41598-024-64696-z.PMID: 38898061; PMCID: PMC11187150.
Basseville A, Cordier C, Ben Azzouz F, Gouraud W, Lasla H, Panloup F, Campone M, Jézéquel P. Brain neural progenitors are new predictive biomarkers for breast cancer hormonotherapy. Cancer Research Communications. 2022 Jul. DOI: 10.1158/2767-9764.CRC-21-0090
Bonneaud TL, Lefebvre CC, Nocquet L, Basseville A, Roul J, Weber H, Campone M, Juin PP, Souazé F. Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death Dis. 2022 Sep 14;13(9):787. doi: 10.1038/s41419-022-05214-9. PMID: 36104324; PMCID: PMC9474880.
Lohard S, Bourgeois N, Maillet L, Gautier F, Fétiveau A, Lasla H, Nguyen F, Vuillier C, Dumont A, Moreau-Aubry A, Frapin M, David L, Loussouarn D, Kerdraon O, Campone M, Jézéquel P, Juin PP, Barillé-Nion S. STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nature Commun. 2020 11:259. doi.org/10.1038/s41467-019-13689-y
Cheray M, Etcheverry A, Jacques C, Pacaud R, Bougras-Cartron G, Aubry M, Denoual F, Peterlongo P, Nadaradjane A, Briand J, Akcha F, Heymann D, Vallette FM, Mosser J, Ory B, Cartron PF. Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme. Mol Cancer. 2020 Feb 25;19(1):36. doi: 10.1186/s12943-020-01155-z.PMID: 32098627

PARTNERSHIP	LABELS		FUNDINGS

CURRENT

Sarah Kamami: Caractérisation phénotypique du cancer du sein par profilage protéomique stochastique

Claire Lalevée: Identification d’opportunités thérapeutiques sur la base du décryptage des méthylomes et du transcriptome des tumeurs

Laurine Berland: EMBRAVE-TNBC: Exploring Mechanisms of Breast Cancer Metastasis through Epithelial-Mesenchymal Transition and Vimentin Expression in Triple-Negative Breast Cancer

Camille Tessier: Development of small-molecule inhibitors of primary ciliogenesis for research on primary cilia

Aurore Dupuy: Investigating the role of the primary cilium in mammary gland remodeling during the reproduction cycle

PAST

Chloé Lefebvre : Role of MCL-1 in myofibroblast phenotype and chemoresistance of fibroblasts associated with breast cancers. Defense on September 16, 2025

Florian Chocteau: Metastatic process in breast cancer after chemotherapy treatment: Immune microenvironment and tumor clonal evolution in the metastatic niche. Defense on February 25, 2025

Alison Dumont: Heterogeneity in the response of breast tumors to antimitotics: What impacts on treatment resistance and immune response? Defense on December 11, 2023

Lisa Nocquet: Implication of BCL-xL and MCL-1 in the metabolic control of cell death by cancer-associated fibroblasts in triple negative breast cancer. Defense on November 30, 2023

Florestan Courant: Cross-species differences or similarities in epigenetic mechanisms induced by pesticides or chemotherapeutic agents. Defense on October 17, 2022

Nina Belaid: Modulation of KRAS activity by BCL-xL: mechanistic aspects and therapeutic implications. Defense on May 18, 2022

Thomas Bonneaud: Consequences of pharmacological targeting of MCL-1 on the myofibroblastic phenotype of breast cancer-associated fibroblasts. Defense on December 3, 2021

Margot Lavy: Regulating myeloid cell activity in tumors through Resolvlne receptors : chemR23. Defense on December 13, 2021

Manon Duforestel: Study of epigenetic mechanisms and dynamics in glioblastoma multiforme during the acquisition of temozolomide resistance. Defense on September 17, 2021

Steven Lohard: STING-dependent paracriny shapes apoptotic priming of breast tumors in response to antimitotic treatment. Defense on May 3, 2019

Josephine Briand: Glioblastoma and epigenetics: from prevention to development of new treatments. Defense on December 12, 2019

Kevin Louault: Role of Cancer-associated fibroblast in apoptosis resistance in breast cancers. Defense on December 19, 2018

Céline Vuillier: Mitochondrial apoptosis regulated by E2F1. Involvement of the E2F1 mitochondrial targeting and interactions with the Bcl-2 Family anti-apoptotic members. Defense on December 19, 2016

Jessie Pécot: BCLxL dependence of cancer cells. Targeting of the dynamic BCLxL/PUMA/BAX network. Oncogenic pathways regulated by the non canonical RAS/BCLxL interaction (October 2015)

Eloise Véquaud: Study of mammary cancer cells response to silencing of surviving by RNA interference or pharmacological targeting: highlighting oh homologous recombination regulation by survivin. (December 2014)

From 2019
Thomas Courouble 2025/26 : Master 2 Biologie-Santé, Université de Reims Champagne-Ardenne, Modélisation moléculaire de l'interaction MCL-1 / NOXA en contexte membranaire
Farida Guira 2025/26 : Master 2 OHNU, Quel rôle de NFkB dans la signalisation de la voie cGAS-STING induite par le taxol dans les TNBC?
Justine Philippe 2025/26 : Master 2 Biologie cellulaire et moléculaire, Université de Rennes, France. Influence de la matrice extra-cellulaire généré par les CAFs sur le phénotype et la chimiorésistance des cellules cancéreuses mammaires
Tom Moraitis 2024/25 : Master 2 Recherche mention « Biologie Santé » parcours Oncologie, immunologie, génétique (OIG). Décryptage d’anomalies épigénétiques/épitranscriptomiques/transcriptomiques associées à la résistance de traitements anti-tumoraux en opportunités thérapeutiques. UFR Sciences et Techniques de l’Université de Rouen Normandie
Marie Gonçalves 2024/25 : Master 2 TOXICOLOGIE ET ECOTOXICOLOGIE PARCOURS TOXICOLOGIE HUMAINE EVALUATION DES RISQUES ET VIGILANCES, Université Paris Cité. Caractérisation de la réponse au stress induit par un ciblage mitochondrial sous influence des fibroblastes associés au cancer pour améliorer la réponse au traitement des cellules cancéreuses du sein triple négatif
Mounia Elhannani 2024/25 : Master 2 Graduate Program Oncologie, Hématologie et médecine NUcléaire (GP-OHNU), Nantes Université, France. Rôle des CAFs dans l’élaboration de matrices extra-cellulaires pro-tumorales et la chimiorésistance des cancers du sein
Quentin Le Borgne 2024/25 : Master 2 I3, Nantes Université, France
Abed-el-Razzak Saleh 2024/25 : Master 2 Graduate Program Oncologie, Hématologie et médecine NUcléaire (GP-OHNU), Nantes Université, France
Morgan Zenatri 2023/24 : Master 2 Biologie-Santé, Nantes Université, France.
Angèle Palierne 2023/24 : Master 2 Biologie-Santé, Nantes Université, France. Etude des mécanismes cellulaires sous-jacents à la résistance aux traitements des cancers du sein induite par les fibroblastes du microenvironnement tumoral
Flavie Bernigole 2023/24 : Master 2 Génétique, Génomique et Biologie des Système, Nantes Université, France. Étude de l'hétérogénéité cellulaire dans la glande mammaire au cours du cycle de reproduction
Claire Lalevée 2023/24 : Master 2 Génétique, Génomique et Biologie des Système, Nantes Université, France. Analyse des profils cellulaires résistants par transcriptomique spatiale dans les cancers du sein réfractaires aux traitements
Audrey Roussel 2022/2023: M2 Biologie Moléculaire et Cellulaire Université de Rennes - Définir l'interactome de MCL-1 par BioID APEX
Mathilde Dupé 2022/23: Master 2 Biologie -Santé (Interactions Cellulaires et Applications Thérapeutiques ) University of Angers, France.Angers. Highlighting therapeutic opportunities induced by studying miRome reprogramming during the development of anastrozole resistance in endometrial cancer.
Aristide Massé 2022/23: Master2 BBRT, University of Nantes, France. Investigating the kinetics of MAM and the impact in the mitochondrial adaptation and resistance acquisition of cancer cells
Camille Tessier 2022/23 : Master 2 Biologie-Santé, Nantes Université, France. Investigating the role of epithelial plasticity and of primary cilia in breast cancer therapeutic resistance
Nicolas Balloud 2022/23: M2 BBRT (Biologie Biotechnologie Recherche Thérapeutique) University of Nantes, France. Deciphering the epigenetic/epitranscriptomic reprogramming associated with acquisition of tolerance/resistance to targeted antitumor therapies
Aurore Dupuy 2021/22: Master 2 "Biologie Moléculaire et Cellulaire", University of Rennes 1, France. Investigating the role of the primary cilium in mammary gland remodeling during the reproduction cycle.
Maxime Richomme 2021/22: Master 2 BBRT, Nantes University
Klara Edern 2021/22: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes "High throughput data analysis to predict tumor cell fate and/or the existence of therapeutic vulnerabilities"
Morgane Allory 2021/22: Master 2 Biologie Santé parcours "Interactions cellulaires et Application thérapeutiques", Angers University. Identification of epigentic and/or epitranscriptomic biomarkers predictive of vulnerabilities to drugs/targeted therapy molecules.
Chloé Lefebvre 2021/22: Master 2 "Biologie, Biotechnologie et Recherche Thérapeutique", Nantes University. Role of MCL-1 in myofibroblast phenotype and chemoresistance of fibroblasts associated with breast cancers.
Hugo Weber 2020/21: Master 2 « Oncologie Moléculaire et Biothérapies », Limoges University. Effect of irradiation on the sensitivity of CAFs and breast adenocarcinoma cancer cells to BH3 mimetics: Evaluation of their therapeutic potential as senolytic agents.
Yuna Landais 2020/2021: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes. "Study of mitochondrial genome methylation by direct nanopore sequencing"
Elen Goujon 2020/2021: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes. "Development of biomedical data analysis pipelines in oncology"
Piera Grisolina 2019/2020: ERASMUS. Master 2 "Biologie Moléculaire et Cellulaire" University of Rennes 1/Tieste University, Italy. Investigating the molecular mechanisms by which EMT programs induce primary ciliogenesis.
Alison Dumont 2019/2020: Master 2 "Biologie, Biotechnologie et Recherche Thérapeutique", Nantes University: Induction of NOXA pro-apoptotic protein expression in response to Paclitaxel in breast tumors: Regulome analysis of its gene transcription.
Louis Paré 2019/2020: Equivalent Master 2 Bioinformatics at Ecole Centrale de Nantes. "Cinetic study of the resistance of anti-tumor treatments by epigenetic genome analysis"

2025

Maillet L, Fétiveau A, Lalier L, Martin N, Barillé-Nion S, Guette C, Gautier F, Téletchéa S, Juin PP. Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism. Nat Commun. 2025 Nov 22. doi: 10.1038/s41467-025-65509-1. Epub ahead of print. PMID: 41274891.
Besson JM, Etcheverry A, Nadaradjane A, Bougras-Cartron G, Aubry M, Frenel JS, Chevanieu A, Lopez M, Mosser J, Cartron PF. Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMT^methylated/DGKI^methylated glioblastoma. Clin Epigenetics. 2025 Aug 30;17(1):146. doi: 10.1186/s13148-025-01943-8. PMID: 40886022; PMCID: PMC12398979.
Tessier CE, Derrien J, Dupuy AMM, Pelé T, Moquet M, Roul J, Douillard E, El Harrif C, Pinson X, Le Gallo M, Godey F, Tas P, Viel R, Grasset E, Prigent C, Letouzé É, Suzanne P, Dallemagne P, Campone M, Weinberg RA, Lees JA, Juin PP, Guen VJ. EMT-ciliary signaling in quasi-mesenchymal-stem-like cells drives therapeutic resistance and is a druggable vulnerability in triple-negative breast cancer. EMBO Mol Med. 2025 Oct;17(10):2536-2561. doi: 10.1038/s44321-025-00289-1. Epub 2025 Aug 26. PMID: 40859055; PMCID: PMC12514032
Lefebvre CC, Giowachini P, Derrien J, Naour M, Corre I, Thirouard L, Douillard E, Chiron D, Guillonneau F, Treps L, Campone M, Juin PP, Souazé F. MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblasts.Cell Death Dis. 2025 Aug 9;16(1):603. doi: 10.1038/s41419-025-07920-6.PMID: 40783386
Dilasser F, Rose L, Quemener A, Ferrandez Y, Hassoun D, Rousselle M, Bergereau H, Lambot SM, Anselmino LE, Trouillet C, Andre G, Maillasson M, Croyal M, Riviere M, Dubreuil D, Collet S, Souaze F, Campone M, Patsouris A, Mortier E, Marquez MM, Juin P, Lebreton J, Tessier A, Cherfils J, Loirand G, Sauzeau V. A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer. Cell Rep Med. 2025 Jul 15;6(7):102233. doi: 10.1016/j.xcrm.2025.102233. Epub 2025 Jul 8. PMID: 40633540; PMCID: PMC12281424..
Gaber M, Quentel A, Holmes J, Lepetit C, Triki H, Wilson A, Payne V, Tenvooren I, Dehours C, Peoples A, Duet ML, Katz AJ, Pécot T, Bougras-Cartron G, Cartron PF, Cook KL, Vidi PA. Obesity increases DNA damage in the breast epithelium. Breast Cancer Res. 2025 Jan 21;27(1):11. doi: 10.1186/s13058-025-01961-7. PMID: 39838489; PMCID: PMC11753040.

2024

Guen VJ, André-Grégoire G, Beauvillain C, Boury F, Chauvet M, Dupuy AMM, Fonteneau JF, Gagne K, Gavard J, Gomez-Bougie P, Grasset E, Jardine J, Lamoureux F, Laurent-Blond M, Letouzé É, Macé Y, Maurice S, Pecqueur C, Pouliquen D, Rbah-Vidal L, Pellat-Deceunynck C, Juin PP. CRCI2NA inaugural symposium: A meeting on tumor and immune ecosystems. Biol Cell. 2024 Nov 9:e202400111. doi: 10.1111/boc.202400111. Epub ahead of print. PMID: 39520372.
Nocquet L, Roul J, Lefebvre CC, Duarte L, Campone M, Juin PP, Souazé F. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts. Sci Rep. 2024 Jun 19;14(1):14177. doi: 10.1038/s41598-024-64696-z. PMID: 38898061; PMCID: PMC11187150.
Jézéquel P, Lasla H, Gouraud W, Basseville A, Michel B, Frenel JS, Juin PP, Ben Azzouz F, Campone M. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype. Breast Cancer. 2024 May 22. doi: 10.1007/s12282-024-01597-z. Epub ahead of print. PMID: 38777987.
Grasset EM, Barillé-Nion S, Juin PP. Stress in the metastatic journey - the role of cell communication and clustering in breast cancer progression and treatment resistance. Dis Model Mech. 2024 Mar 1;17(3):dmm050542. doi: 10.1242/dmm.050542. Epub 2024 Mar 20. PMID: 38506114; PMCID: PMC10979546
Tessier CE, Dupuy AMM, Pelé T, Juin PP, Lees JA, Guen VJ. EMT and primary ciliogenesis: For better or worse in sickness and in health. Genesis. 2024 Feb;62(1):e23568. doi: 10.1002/dvg.23568. Epub 2023 Nov 9. PMID: 37946671

2023

Dupuy AMM, Juin PP, Guen VJ. Using mammary organoids to study cilia. Methods Cell Biol. 2023;175:221-233. doi: 10.1016/bs.mcb.2022.09.010. PMID: 36967142.
Lavy M, Gauttier V, Dumont A, Chocteau F, Deshayes S, Fresquet J, Dehame V, Girault I, Trilleaud C, Neyton S, Mary C, Juin P, Poirier N, Barillé-Nion S, Blanquart C. ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Front Immunol. 2023 Jul 19;14:1196731. doi: 10.3389/fimmu.2023.1196731. PMID: 37539056;
Bougras-Cartron G, Nadaradjane A, Joalland MP, Lalier-Bretaudeau L, Raimbourg J, Cartron PF. Adenosine Methylation Level of miR-125a-5p Promotes Anti-PD-1 Therapy Escape through the Regulation of IGSF11/VSIG3 Expression. Cancers (Basel). 2023 Jun 14;15(12):3188. doi: 10.3390/cancers15123188. PMID: 37370798;
Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, Ducray F, Enz-Werle N, Figarella-Branger D, Fournier I, Frenel JS, Gabut M, Galli T, Gavard J, Huberfeld G, Hugnot JP, Idbaih A, Junier MP, Mathivet T, Menei P, Meyronet D, Mirjolet C, Morin F, Mosser J, Moyal EC, Rousseau V, Salzet M, Sanson M, Seano G, Tabouret E, Tchoghandjian A, Turchi L, Vallette FM, Vats S, Verreault M, Virolle T. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer. 2023 Jan;9(1):9-27. doi: 10.1016/j.trecan.2022.09.005.

2022

Courant F, Bougras-Cartron G, Abadie C, Frenel JS, Cartron PF. Modulation of DNA Methylation/Demethylation Reactions Induced by Nutraceuticals and Pollutants of Exposome Can Promote a C > T Mutation in the Breast Cancer Predisposing Gene PALB2. Epigenomes. 2022 Sep 30;6(4):32. doi: 10.3390/epigenomes6040032. PMID: 36278678
Wilson MM, Callens C, Le Gallo M, Mironov S, Ding Q, Salamagnon A, Chavarria TE, Viel R, Peasah AD, Bhutkar A, Martin S, Godey F, Tas P, Kang HS, Juin PP, Jetten AM, Visvader JE, Weinberg RA, Attanasio M, Prigent C, Lees JA, Guen VJ. An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. Sci Adv. 2021 Oct 29;7(44):eabf6063.
Bonneaud TL, Lefebvre CC, Nocquet L, Basseville A, Roul J, Weber H, Campone M, Juin PP, Souazé F. Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death Dis. 2022 Sep 14;13(9):787. doi: 10.1038/s41419-022-05214-9.
Lalier L, Vallette F, Manon S. Bcl-2 Family Members and the Mitochondrial Import Machineries: The Roads to Death. Biomolecules. 2022 Jan 19;12(2):162.
Garnier D, Ratcliffe E, Briand J, Cartron PF, Oliver L, Vallette FM. The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p. Biomedicines. 2022 Jan 6;10(1):112.

2021

Wilson MM, Callens C, Le Gallo M, Mironov S, Ding Q, Salamagnon A, Chavarria TE, Viel R, Peasah AD, Bhutkar A, Martin S, Godey F, Tas P, Kang HS, Juin PP, Jetten AM, Visvader JE, Weinberg RA, Attanasio M, Prigent C, Lees JA, Guen VJ. An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. Sci Adv. 2021 Oct 29;7(44):eabf6063.
Hazan R, Mori M, Danielian PS, Guen VJ, Rubin SM, Cardoso WV, Lees JA. E2F4's cytoplasmic role in multiciliogenesis is mediated via an N-terminal domain that binds two components of the centriole replication machinery, Deup1 and SAS6. Mol Biol Cell. 2021 Oct 1;32(20):ar1.
Lavy M, Gauttier V, Poirier N, Barillé-Nion S, Blanquart C. Specialized Pro-Resolving Mediators Mitigate Cancer-Related Inflammation: Role of Tumor-Associated Macrophages and Therapeutic Opportunities. Front. Immunol., 30 June 2021 | https://doi.org/10.3389/fimmu.2021.702785.
Tea I, De Luca A, Schiphorst AM, Grand M, Barillé-Nion S, Mirallié E, Drui D, Krempf M, Hankard R, Tcherkez G. Stable Isotope Abundance and Fractionation in Human Diseases. Metabolites. 2021 Jun 9;11(6):370.
Duclos M, Prigent C, Le Borgne R, Guen VJ. Three-Dimensional Imaging of Organoids to Study Primary Ciliogenesis During ex vivo Organogenesis. J Vis Exp. 2021 May 14;(171).
Jézéquel P, Gouraud W, Ben Azzouz F, Guérin-Charbonnel C, Juin PP, Lasla H, Campone M. bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database (Oxford). 2021 Feb 18; 2021:baab007. doi: 10.1093/database/baab007.
Ben Azzouz F, Michel B, Lasla H, Gouraud W, François AF, Girka F, Lecointre T, Guérin-Charbonnel C, Juin PP, Campone M, Jézéquel P. Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approaches. Comput Biol Med. 2021 Feb;129:104171. doi: 10.1016/j.compbiomed.2020.104171.
Lalier L, Mignard V, Joalland MP, Lanoé D, Cartron PF, Manon S, Vallette FM. TOM20-mediated transfer of Bcl2 from ER to MAM and mitochondria upon induction of apoptosis. Cell Death Dis. 2021 Feb 15;12(2):182.
Olivier C, Oliver L, Lalier L, Vallette FM. Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress. Front Mol Biosci. 2021 Jan 27;7:620677.

2020

Guyon N, Garnier D, Briand J, Nadaradjane A, Bougras-Cartron G, Raimbourg J, Campone M, Heymann D, Vallette FM, Frenel JS, Cartron PF. Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells. Cell Death Dis. 2020 Dec 11;11(12):1048. doi: 10.1038/s41419-020-03224-z.
Nocquet L, Juin PP, Souazé F. Mitochondria at Center of Exchanges between Cancer Cells and Cancer-Associated Fibroblasts during Tumor Progression. Cancers (Basel). 2020 Oct 17;12(10):3017. doi: 10.3390/cancers12103017.
Guen VJ, Prigent C. Targeting Primary Ciliogenesis with Small-Molecule Inhibitors. Cell Chem Biol. 2020 Oct 15;27(10):1224-1228.
Peixoto P, Cartron PF, Serandour AA, Hervouet E. From 1957 to Nowadays: A Brief History of Epigenetics. Int J Mol Sci. 2020 Oct 14;21(20):7571. doi: 10.3390/ijms21207571. PMID: 33066397;
Wilson MM, Weinberg RA, Lees JA, Guen VJ. Emerging Mechanisms by which EMT Programs Control Stemness. Trends Cancer. 2020 Sep;6(9):775-780.
Briand J, Sérandour AA, Nadaradjane A, Bougras-Cartron G, Heymann D, Ory B, Vallette FM, Cartron PF. N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool. Mol Ther Nucleic Acids. 2020 Aug 14;22:72-83. doi: 10.1016/j.omtn.2020.08.010.
Oliver L, Lalier L, Salaud C, Heymann D, Cartron PF, Vallette FM. Drug resistance in glioblastoma: are persisters the key to therapy? Cancer Drug Resist. 2020 Aug 7;3(3):287-301. doi: 10.20517/cdr.2020.29.
Mignard V, Dubois N, Lanoé D, Joalland MP, Oliver L, Pecqueur C, Heymann D, Paris F, Vallette FM, Lalier L. Sphingolipid distribution at mitochondria-associated membranes (MAMs) upon induction of apoptosis. J Lipid Res. 2020 Jul;61(7):1025-1037.
Barillé-Nion S, Lohard S, Juin PP: Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses? Biomolecules 2020 Jul 25;10(8):E1109. doi: 10.3390/biom10081109.
Lohard S, Juin PP, Barillé-Nion S. Mitotic stress-induced secretome primes cancer cells to apoptosis and maximizes paclitaxel response in breast tumors when combined with BCL-xL-targeting BH3 mimetics. Mol Cell Oncol. 2020 Mar 19;7(3):1735912. doi: 10.1080/23723556.2020.1735912.
Briand J, Garnier D, Nadaradjane A, Clément-Colmou K, Potiron V, Supiot S, Bougras-Cartron G, Frenel JS, Heymann D, Vallette FM, Cartron PF. Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity. Epigenomics. 2020 Mar;12(5):397-408. doi: 10.2217/epi-2019-0193.
Cheray M, Etcheverry A, Jacques C, Pacaud R, Bougras-Cartron G, Aubry M, Denoual F, Peterlongo P, Nadaradjane A, Briand J, Akcha F, Heymann D, Vallette, FM, Mosser J, Ory B, Cartron PF. Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme. Mol Cancer. 2020 Feb 25;19(1):36. doi: 10.1186/s12943-020-01155-z.
Lohard S, Bourgeois N, Maillet L, Gautier F, Fétiveau A, Lasla H, Nguyen F, Vuillier C, Dumont A, Moreau-Aubry A, Frapin M, David L, Loussouarn D, Kerdraon O, Campone M, Jézéquel P, Juin PP, Barillé-Nion S. STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nature Communications. 2020 11:259. doi.org/10.1038/s41467-019-13689-y
Duforestel M, Briand J, Bougras-Cartron G, Heymann D, Frenel JS, Vallette FM, Cartron PF. Cell-free circulating epimarks in cancer monitoring. Epigenomics. 2020 Jan;12(2):145-155. doi: 10.2217/epi-2019-0170.
Cartron PF, Cheray M, Bretaudeau L. Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer. Epigenomics. 2020 Jan;12(2):171-177. doi: 10.2217/epi-2019-0169.
Rabé M, Dumont S, Álvarez-Arenas A, Janati H, Belmonte-Beitia J, Calvo GF, Thibault-Carpentier C, Séry Q, Chauvin C, Joalland N, Briand F, Blandin S, Scotet E, Pecqueur C, Clairambault J, Oliver L, Perez-Garcia V, Nadaradjane A, Cartron PF, Gratas C, Vallette FM. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis. 2020 Jan 6;11(1):19.

2019

Avril P, Vidal L, Barille-Nion S, Le Nail LR, Redini F, Layrolle P, Pinault M, Chevalier S, Perrot P, Trichet V. Epinephrine Infiltration of Adipose Tissue Impacts MCF7 Breast Cancer Cells and Total Lipid Content. Int J Mol Sci. 2019 Nov 11;20(22). pii: E5626.
Briand J, Nadaradjane A, Bougras-Cartron G, Olivier C, Vallette FM, Cartron PF. Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation. Clin Epigenetics. 2019 Nov 14;11(1):159. doi: 10.1186/s13148-019-0759-1.
Duforestel M, Nadaradjane A, Bougras-Cartron G, Briand J, Olivier C, Frenel JS, Vallette FM, Lelièvre SA, Cartron PF. Glyphosate Primes Mammary Cells for Tumorigenesis by Reprogramming the Epigenome in a TET3-Dependent Manner. Front Genet. 2019 Sep 27;10:885. doi: 10.3389/fgene.2019.00885.
Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, Lalier L, Cartron PF, Heymann D. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochem Pharmacol. 2019 Apr;162:169-176. doi: 10.1016/j.bcp.2018.11.004.
Louault K, Bonneaud TL, Séveno C, Gomez-Bougie P, Nguyen F, Gautier F, Bourgeois N, Loussouarn D, Kerdraon O, Barillé-Nion S, Jézéquel P, Campone M, Amiot M, Juin PP, Souazé F. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. Oncogene. 2019 Apr;38(17):3261-3273. doi: 10.1038/s41388-018-0635-z.
Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today. 2019 Mar;24(3):763-772. doi: 10.1016/j.drudis.2018.11.017.
Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Epigenetic Metalloenzymes. Curr Med Chem. 2019;26(15):2748-2785.
Ramana Murthy AV, Narendar V, Kumar NS, Aparna P, Durga Bhavani AK, Gautier F, Barillé-Nion S, Juin P, Mosset P, Grée R, Levoin N. Targeting PUMA/Bcl-xL interaction by new specific compounds to unleash apoptotic process in cancer cells. Eur J Med Chem. 2019 Jan 15;162:334-347.

Offers

If like us, you are interested in understanding cancers and imagining tomorrow’s personalized medicine in oncology, do not hesitate to contact us.

Master 2

No specific announcement at the moment.

PhD Thesis

No specific announcement at the moment.

Post docs

No specific announcement at the moment.

Others job opportunities

No specific announcement at the moment.
However, if you are interested in joining the team, please feel free to submit your spontaneous applications to philippe.juin@inserm.fr